Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Fundamental Analysis of Ajanta Pharma Ltd

About the Company - Ajanta Pharma Ltd

Ajanta Pharma Ltd. is a Public Limited Listed company incorporated on 31/12/1979 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1979PLC022059 and registration number is 022059. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3140.64 Cr. and Equity Capital is Rs. 17.17 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAjanta House, Charkop, Mumbai Maharashtra 400067info@ajantapharma.com
http://www.ajantapharma.com
Management
NamePosition Held
Mr. Mannalal B AgrawalChairman
Mr. Madhusudan B AgrawalVice Chairman
Mr. Yogesh M AgrawalManaging Director
Mr. Rajesh M AgrawalJoint Managing Director
Mr. Chandrakant M KhetanIndependent Director
Mr. K H ViswanathanIndependent Director
Mr. Prabhakar R DalalIndependent Director
Dr. Anjana GrewalIndependent Director

Ajanta Pharma Ltd. Share Price Update

Share PriceValue
Today₹1,958.45
Previous Day₹1,944.90

Basic Stock Data of Ajanta Pharma Ltd

Market Cap 24,620 Cr.
Current Price 1,955
High / Low2,054/1,132
Stock P/E37.3
Book Value 277
Dividend Yield0.51 %
ROCE22.6 %
ROE17.9 %
Face Value 2.00

Ajanta Pharma Ltd Quarterly Results

Month

Ajanta Pharma Ltd Quarterly Chart

Ajanta Pharma Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales6779311,2081,4741,7491,9832,1262,0552,5882,8903,3413,7433,903
Expenses5457068409681,1551,2921,4671,4891,9041,8892,4082,9343,022
Operating Profit1322243695055946916585676831,001933808881
OPM %19%24%31%34%34%35%31%28%26%35%28%22%23%
Other Income6614814202421882411274125
Interest15199651011281067
Depreciation323444524461607296116125131133
Profit before tax91177330456559648623514664900909745865
Tax %15%37%29%32%26%22%25%25%30%27%22%21%
Net Profit77112234310416507469387468654713588660
EPS in Rs5.858.4917.7523.4731.4938.4035.5029.5635.7350.3855.6345.8951.52
Dividend Payout %11%13%15%17%17%23%0%20%24%13%11%15%

Ajanta Pharma Ltd Profit & Loss Yearly Chart

Ajanta Pharma Ltd Growth

Compounded Sales Growth
10 Years::15%
5 Years::12%
3 Years::13%
TTM::9%

Ajanta Pharma Ltd Growth

Compounded Profit Growth
10 Years::18%
5 Years::5%
3 Years::8%
TTM::-2%

Ajanta Pharma Ltd Growth

Stock Price CAGR
10 Years::23%
5 Years::23%
3 Years::20%
1 Year::58%

Ajanta Pharma Ltd Growth

Return on Equity
10 Years::25%
5 Years::20%
3 Years::21%
Last Year::18%

Ajanta Pharma Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital12121818181818181817172525
Reserves2863825768231,1731,5502,0242,2282,5812,9783,2473,3633,457
Borrowings200125130728112367531253633
Other Liabilities1512002262332072543833836197027111,159918
Total Liabilities6497189491,1461,4791,8232,4262,6643,2933,7294,0004,5824,433
Fixed Assets2462732792884515891,0531,1781,4721,5411,5121,4961,485
CWIP3129417024033961262132108153209205
Investments886360861821907879176147535238
Other Assets3924255136297037131,1221,1471,6101,9042,1882,3412,506
Total Assets6497189491,1461,4791,8232,4262,6643,2933,7294,0004,5824,433

Ajanta Pharma Ltd Reserves and Borrowings Chart

Ajanta Pharma Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 70234212279326609281375457576562792
Cash from Investing Activity -53-104-188-158-209-383-256-223-224-282-74-560
Cash from Financing Activity -13-104-20-105-117-202-0-147-129-318-460-108
Net Cash Flow426416-024254104-2428124

Ajanta Pharma Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days765961647859798210993111103
Inventory Days266178164159180186315415276434347283
Days Payable161159132109128157224214202212143147
Cash Conversion Cycle182789411413088170282184315315240
Working Capital Days93595761906510311911612714183
ROCE %23%39%55%57%52%46%34%24%27%32%29%23%

Ajanta Pharma Ltd Financial Efficiency Indicators Chart

Ajanta Pharma Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters70.34%70.34%70.34%70.34%70.34%70.48%70.48%70.48%66.11%66.11%66.22%66.22%
FIIs7.90%8.37%8.94%8.72%8.95%8.64%8.30%8.23%10.07%10.00%10.19%9.99%
DIIs11.72%11.86%11.81%12.07%12.14%12.29%12.46%12.68%15.37%15.52%15.36%15.60%
Government0.76%0.76%0.43%0.43%0.45%0.45%0.45%0.45%0.45%0.45%0.46%0.00%
Public9.27%8.67%8.47%8.43%8.12%8.14%8.31%8.15%8.00%7.91%7.78%8.21%
No. of Shareholders49,45944,88145,67252,26357,89760,75964,44562,04859,79883,54954,87456,277

Ajanta Pharma Ltd Shareholding Pattern Chart

No. of Ajanta Pharma Ltd Shareholders

Ajanta Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
UTI Flexi Cap Fund23428761.58404.71
Kotak Small Cap Fund - Regular Plan7741421.09133.73
UTI Value Opportunities Fund6656111.52114.98
HDFC Balanced Advantage Fund - Regular Plan6586260.18113.77
Invesco India Contra Fund5375000.8392.85
Franklin India Prima Fund5271731.0491.06
Mirae Asset Midcap Fund3897520.5667.33
Tata Large & Mid Cap Fund - Regular Plan3279371.1156.65
Tata Large & Mid Cap Fund - Regular Plan3279371.1156.65
UTI Long Term Equity Fund2950001.6250.96

Ajanta Pharma Ltd ROCE Trend

Ajanta Pharma Ltd EPS Trend

Ajanta Pharma Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)45.8982.4575.0953.6043.97
Diluted EPS (Rs.)45.8982.4575.0953.6043.96
Cash EPS (Rs.)56.8997.6188.5564.2452.34
Book Value[Excl.RevalReserv]/Share (Rs.)268.14380.24344.52296.34256.01
Book Value[Incl.RevalReserv]/Share (Rs.)268.14380.24344.52296.34256.01
Revenue From Operations / Share (Rs.)296.21389.17332.34295.08234.36
PBDIT / Share (Rs.)69.80121.72117.8388.4366.99
PBIT / Share (Rs.)59.45107.13104.4877.5158.77
PBT / Share (Rs.)58.98105.94103.5375.7158.64
Net Profit / Share (Rs.)46.5483.0175.2053.3344.12
NP After MI And SOA / Share (Rs.)46.5483.0175.2053.3344.12
PBDIT Margin (%)23.5631.2735.4529.9628.58
PBIT Margin (%)20.0627.5231.4326.2625.07
PBT Margin (%)19.9127.2231.1525.6525.02
Net Profit Margin (%)15.7121.3322.6218.0718.82
NP After MI And SOA Margin (%)15.7121.3322.6218.0718.82
Return on Networth / Equity (%)17.3521.8321.8217.9917.23
Return on Capital Employeed (%)21.2126.9829.0225.0622.23
Return On Assets (%)12.5617.5717.3014.0914.35
Total Debt / Equity (X)0.000.000.000.010.01
Asset Turnover Ratio (%)0.810.830.790.760.71
Current Ratio (X)2.493.503.132.713.13
Quick Ratio (X)1.772.281.941.891.97
Inventory Turnover Ratio (X)1.191.101.251.281.02
Dividend Payout Ratio (NP) (%)15.2511.5312.6724.2520.47
Dividend Payout Ratio (CP) (%)12.479.8110.7620.1317.25
Earning Retention Ratio (%)84.7588.4787.3375.7579.53
Cash Earning Retention Ratio (%)87.5390.1989.2479.8782.75
Interest Coverage Ratio (%)151.01102.45123.8965.11506.47
Interest Coverage Ratio (Post Tax) (%)101.6870.8780.0740.60334.59
Enterprise Value (Cr.)14945.6115321.6715384.3011819.918970.10
EV / Net Operating Revenue (X)3.994.595.324.574.36
EV / EBITDA (X)16.9514.6615.0215.2415.27
MarketCap / Net Operating Revenue (X)4.084.655.404.634.40
Retention Ratios (%)84.7488.4687.3275.7479.52
Price / BV (X)4.514.765.214.614.02
Price / Net Operating Revenue (X)4.084.655.404.634.40
EarningsYield0.030.040.040.030.04

Ajanta Pharma Ltd Profitability Ratios (%)

Ajanta Pharma Ltd Liquidity Ratios

Ajanta Pharma Ltd Liquidity Ratios (%)

Ajanta Pharma Ltd Interest Coverage Ratios (%)

Ajanta Pharma Ltd Valuation Ratios

Strength and Weakness of Ajanta Pharma Ltd Stock

StrengthWeakness

The company has higher reserves compared to borrowings, indicating strong financial stability.

The company has shown consistent growth in sales and profit over the years.

The stock has a low average ROCE, which may not be favorable.

The stock has a high average Working Capital Days, which may not be favorable.

The stock has a high average Cash Conversion Cycle, which may not be favorable.

More Stocks